Vitals Knowledge Vault

Glycine NAC Sleep Stack

6 min read

Glycine NAC Sleep Stack

Evidence gap label: This stack combination — glycine + NAC — has no human clinical trials. Claims of additive or synergistic benefit are unsupported. Each component is treated separately below.

TL;DR

  • Glycine (3 g pre-sleep): Supported evidence for sleep onset latency reduction and next-day alertness in adults with poor sleep quality; small RCTs (n=9–30), Japanese populations, short duration (2–4 weeks)
  • NAC (600–1,800 mg pre-sleep): Supported evidence for sleep quality in populations with elevated oxidative stress (COPD, psychiatric); Gap in healthy adults without oxidative stress
  • Combination: Gap — no study has examined glycine + NAC together for any sleep outcome
  • Both compounds are off-label for sleep; neither is FDA-approved for this indication

Why it matters for Vitals

Sleep architecture optimization is a core Vitals longevity domain. Glycine is one of the few supplemental interventions with replicated (if small) RCT evidence for sleep onset latency reduction. For users with elevated oxidative stress — metabolic syndrome, aging, high training load — NAC has a plausible peripheral antioxidant mechanism. The practical value proposition:

  • Glycine is a low-risk, modest-effect sleep-onset aid; consistent evidence direction across trials
  • NAC can be considered only with explicit evidence boundaries disclosed; healthy-adult sleep benefit is unproven
  • The combination should not be presented as evidence-backed or synergistic

Human signoff required before inclusion in any Vitals coaching protocol: confirm no sulfa allergy (NAC cross-reactivity concern), no cystinuria or kidney stones, no seizure disorder, and not pregnant or breastfeeding.

Key Facts

GlycineNAC
Dose1–3 g pre-sleep600–1,800 mg pre-sleep
Best evidence forSleep onset latency (−5–10 min), next-day alertnessSleep quality in oxidative-stress populations (COPD, psychiatric)
MechanismPeripheral vasodilation → core temp drop; inhibitory GlyR neurotransmissionGlutathione precursor; peripheral GSH elevation proven; CNS elevation at oral doses Contested
SafetyGRAS; well-tolerated up to 30 g/day for 4 weeksGI upset at higher doses; mild anticoagulant effect at high doses
Regulatory statusGRAS (not approved for sleep)Approved for acetaminophen overdose / mucolytic (not approved for sleep)

Mechanism Summary

Glycine initiates sleep via two pathways:

  1. Thermoregulatory (best supported in humans): Peripheral vasodilation in extremities → increased heat loss → core body temperature drop. This accelerates the natural pre-sleep temperature decline that facilitates sleep onset. Evidence: PMID-11774038 — Supported

  2. Inhibitory neurotransmission: Glycine acts at glycine receptors (GlyR) in brainstem and spinal cord, antagonizing NMDA/AMPA activity and producing neuronal hyperpolarization. Evidence: PMID-12453916 — Supported

Glycine crosses the BBB via SAT1 and SNAT2 transporters; CNS levels rise after oral ingestion (Evidence: PMID-17124091 — Supported). The quantitative relationship between CNS glycine at 1–3 g oral doses and sleep onset is Contested.

NAC addresses sleep quality via antioxidant pathways:

  1. Peripheral glutathione elevation (Confirmed): NAC is a cysteine prodrug; cysteine is the rate-limiting amino acid for GSH synthesis. Oral NAC raises plasma and peripheral tissue GSH. Evidence: PMID-14636991 — Confirmed

  2. CNS glutathione elevation at oral supplemental doses (Contested): Whether 600–1,800 mg oral NAC raises brain GSH in humans is not demonstrated; most CNS data used IV NAC.

  3. Nrf2/ARE pathway (Gap): Animal data only; human sleep relevance unproven. Evidence: PMID-24359224

The combination addresses different physiological axes (sleep initiation vs. sleep quality via oxidative stress). No synergistic or additive benefit has been studied. Claim grade: Gap

See: Glycine Sleep Mechanism

What the Current Evidence Suggests

Glycine

  • Sleep onset latency reduced by ~5–10 min in poor sleepers (PMID-21233519, Supported)
  • Next-day alertness improved (PMID-16944695, Supported)
  • SWS minutes may increase (PMID-22872576, Reported; n=9, PSG-validated, needs replication)
  • All trials small (n ≤ 30), short duration (2–4 weeks), Japanese populations
  • Long-term (>3-month) sleep-specific safety data absent

NAC

  • Sleep quality improved in COPD patients with nocturnal oxidative stress (PMID-2298262, Supported; n=44)
  • Insomnia Severity Index reduced in psychiatric patients (PMID-26229607, Reported; n=35, 2,400 mg/day)
  • No evidence for sleep benefit in healthy adults without oxidative stress or inflammatory conditions (Confirmed gap)
  • No combination RCT for glycine + NAC exists (Confirmed gap)

Vitals Wearable Relevance

SignalWearableExpected DirectionEvidence
Sleep onset latencyOura, Whoop, Apple WatchGlycine: improvement; NAC: no expected effect in healthy adultsGlycine: PMID-21233519 Supported; NAC: Gap
Sleep efficiencyOura, Whoop, Apple WatchSecondary improvement to SOL reductionGlycine: PMID-21233519 Reported
HRV (nightly RMSSD)Oura, Whoop, Apple WatchDirection unknown; temperature mechanism may affect HRVContested
Next-day readinessOura readiness, Whoop recoveryGlycine: alertness improvement SupportedPMID-16944695
SWS minutesWearable algorithm (not EEG-validated)Direction unknown; evidence absentGlycine: PMID-22872576 Reported; NAC: Gap

Important: All wearable sleep-stage and HRV data are algorithm-estimated, not PSG-derived. Single-night comparisons are too noisy for clinical use. 7-day averages are the minimum meaningful window.

CGM has no established role in glycine + NAC sleep optimization; blood glucose variability is not a recognized mechanism. Evidence: Gap

Risks and Uncertainty

Glycine

  • Long-term (>3-month) sleep-specific safety data absent (Gap)
  • Pregnancy/lactation: insufficient safety data (Gap)
  • High-dose (>20 g) rare seizure association; not relevant at ≤3 g sleep dose (Low risk)
  • Next-day grogginess reported at higher doses in some users; titrate from 1 g

NAC

  • GI upset: nausea, diarrhea, abdominal cramping in ~10–15% at higher doses (Mild)
  • Mild anticoagulant properties; caution with warfarin, DOACs, antiplatelet agents (Supported)
  • Effervescent formulations contain ~250 mg sodium per 600 mg tablet (Mild)
  • Source quality variable; DMF contamination in low-quality NAC; use USP-verified product (Mild-moderate)
  • Pregnancy/lactation: safety not established (Gap)
  • NAC + carbamazepine co-administration: both hepatically metabolized; clinician supervision required (Human signoff required)

Combination

  • No combination safety data exist (Confirmed Gap)
  • Users combining both compounds are in an unstudied situation

Contraindications (all require human signoff)

  • Sulfa drug allergy (NAC): theoretical cross-reactivity
  • Cystinuria or kidney stone history (NAC)
  • Seizure disorder
  • Anticoagulant/antiplatelet therapy
  • Pregnancy or breastfeeding (both compounds)

Best Stack Context

  • Glycine alone is appropriate as a first-line sleep-onset aid for users with poor sleep quality and no contraindications; start at 1 g, titrate to 3 g
  • NAC alone is appropriate only for users with elevated oxidative stress (COPD, metabolic syndrome, high training load, aging); evidence boundary must be disclosed; human signoff required
  • Glycine + NAC combination: experimental only; not appropriate for general Vitals coaching without explicit disclosure that no human evidence exists

See also: Sleep Onset Latency, Sleep Architecture, Melatonin Beyond Sleep

Graph View

Backlinks